Loading
Life sciences · Journal article
BMC Pulmonary Medicine · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
HER2 overexpression is a key resistance mechanism to osimertinib in EGFR-mutant non-small cell lung cancer (NSCLC). However, real-world evidence remains limited. This first real-world study included 3,589 EGFR-mutant NSCLC patients from six PLAGH medical centers, and 50 patients with HER2 overexpression (immunohistochemistry (IHC) 2+/3+) met the inclusion criteria. HER2 overexpression was either present at diagnosis ( n = 33, Cohort P) or acquired under osimertinib therapy ( n = 17, Cohort A). Clinicopathological data, objective response rate (ORR), progression-free survival (PFS), and adverse events were analyzed. The most common EGFR mutation was exon 21 L858R ( n = 29), and TP53 ( n = 24) was the most common co-mutation. In Cohort P, 3 patients received trastuzumab deruxtecan (T-DXd) plus osimertinib achieved PFS exceeding 14.0 months (individual PFS: 14.0, 15.8, and 29.0 months), with the ORR of 66.7%. The mPFS in Cohort P patients who did not receive T-DXd plus osimertinib ( n = 30) was 6.7 months (95% CI, 3.7–9.7). In Cohort A, 7 patients received T-DXd plus osimertinib, with an ORR of 14.3% and an mPFS of 13.2 months (95% CI, 7.0-19.4), compared with 3.8 months (95% CI, 2.9–4.7) in those not receiving T-DXd plus osimertinib ( n = 10). Treatment-related adverse events occurred in 100.0% of patients receiving T-DXd plus osimertinib (mostly grade 1–2), with hematologic AEs as the most common type. In summary, T-DXd plus EGFR-TKI may offer clinical benefit for patients with HER2 overexpression after osimertinib resistance. However, the potential role of this combination must be tested in prospective trials. Not Applicable.